Prosight Management
$580M 13F equity value
51 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Prosight Management covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| LKFT | LAKEFRONT BIOTHERAPEUTICS NV | 2,043,344 | $61M | 10.6% |
| JANX | JANUX THERAPEUTICS INC | 3,804,481 | $58M | 10.1% |
| NKTR | NEKTAR THERAPEUTICS | 810,000 | $57M | 9.7% |
| BSX | BOSTON SCIENTIFIC CORP | 1,270,273 | $54M | 9.3% |
| STTK | SHATTUCK LABS INC | 5,957,877 | $41M | 7.1% |
| INSM | INSMED INC | 375,609 | $40M | 6.9% |
| ALNY | ALNYLAM PHARMACEUTICALS INC | 98,080 | $30M | 5.1% |
| SNDX | SYNDAX PHARMACEUTICALS INC | 1,200,000 | $26M | 4.5% |
| KURA | KURA ONCOLOGY INC | 2,021,964 | $22M | 3.8% |
| ALKS | ALKERMES PLC | 394,389 | $21M | 3.6% |
Track Prosight Management's 13F portfolio: $580M in reported holdings, 51 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}